This was associated with decreased expression of the SMYD2 protein substrates EZH2, p65, p-mTOR, and p-MAPK in OC-PF-treated primary tumor samples compared to in the placebo control-treated animal tumors. The gene discussed is EZH2; the disease is neoplasm.